Xenon Pharmaceuticals Inc. (XENE)
After hours:
| Previous close | 39.04 |
| Open | 39.37 |
| Bid | 30.00 x 2200 |
| Ask | 61.37 x 1100 |
| Day's range | 38.25 - 40.33 |
| 52-week range | 27.99 - 43.75 |
| Volume | |
| Avg. volume | 598,185 |
| Market cap | 2.886B |
| Beta (5Y monthly) | 1.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain
Key Insights Significantly high institutional ownership implies Xenon Pharmaceuticals' stock price is sensitive to...
- Zacks
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
Xenon (XENE) posts top-line data from a phase II proof-of-concept study evaluating its pipeline candidate, XEN1101, for treating moderate-to-severe major depressive disorder. Stock rises.
- Reuters
UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study
Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episodes compared to a placebo, in a mid-stage study. Still, the company said it was actively exploring future development of the drug candidate, XEN1101, as a treatment for MDD. Xenon said the study data was compelling, building upon the ongoing late-stage study for the use of XEN1101 in treating epilepsy.
